Official Publication of the International Conference & Exhibition
This message contains images. If you don't see images, click here to view.
Advertise in this news brief.


Text version   RSS   Subscribe   Unsubscribe   Archive   Media Kit May 31, 2017    SLAS2018    Moving? New job? Let SLAS know.      







Thank You, Corning Life Sciences!
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Corning Life Sciences has sponsored free online access to select articles in the June 2017 SLAS Discovery Special Issue on 3D Cell Culture, Drug Screening, and Optimization:

  • From the Guest Editors: Three-Dimensional Cell Culture – A Rapidly Emerging Approach to Cellular Science and Drug Discovery

  • Three-Dimensional Cell Cultures in Drug Discovery and Development

  • 3D Models of the NCI60 Cell Lines for Screening Oncology Compounds

  • A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth

  • A 1536-Well 3D Viability Assay to Assess the Cytotoxic Effect of Drugs on Spheroids

  • RNAi High-Throughput Screening of Single- and Multi-Cell-Type Tumor Spheroids: A Comprehensive Analysis in Two and Three Dimensions

  • Exploring Drug Dosing Regimens In Vitro using Real Time Three Dimensional (3D) Spheroid Tumor Growth Assays

  • More


    Abstracts Due June 5
    SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    The SLAS Europe 2017 High-Content Screening Conference is Sept. 19-20 in Madrid, Spain. Scientific abstract proposals from research scientists, engineers, academics and business leaders are being accepted until Monday, June 5.

    Conference topics revolve around four topics: data analysis, screening, technology and model systems. Take advantage of this opportunity to interact with a stellar HCS community in Europe.

    SLAS ELN Reports: Bridging the Gap — Bringing 3D Cell Culture and Phenotypic Drug Screening Together
    SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    What happens when several scientific disciplines join forces to tackle one of the biggest challenges in drug discovery and development? You get "a fast-moving field with a lot of innovation and a lot of exciting research," says Richard Eglen, Ph.D., of Corning Life Sciences, former SLAS president and a guest editor of the June 2017 SLAS Discovery Special Issue on 3D Cell Culture, Drug Screening and Optimization.

    He and co-guest editor Jean-Louis Klein, Ph.D., of GlaxoSmithKline have collected 17 outstanding peer-reviewed papers that highlight important new advances in 3D culture technology and its use in drug development. Thanks to the generosity of Corning Life Sciences, free online access to select reports is available. Learn more from the guest editors in the SLAS Electronic Laboratory Neighborhood e-zine feature article.

    Improve high-throughput Fragment Analysis

    Accelerate your high-throughput DNA fragment analysis with the ZAG DNA Analyzer from Advanced Analytical. With the ZAG, you can separate up to 48, 96-well sample plates every 24 hours, providing you with the results you need, when you need them. Find out why the ZAG is perfect for you.

    Congratulations Karsten Boehnke of Eli Lilly & Company (Spain)
    SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Boehnke is the top vote-getter in the 2017 SLAS Discovery & SLAS Technology Art of Science Contest — and winner of a $500 Amazon gift card — for his striking image showing the complex morphology of a patient-derived 3D organoid culture using confocal microscopy by merging several z slices.

    Boehnke says patient-derived organoid cultures represent a new generation of experimental 3D model systems for translational research, drug-screening technology and pharmacogenomic profiling. Learn more about his work in "Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures" in SLAS Discovery.

    SLAS Technology Podcast Series: Conversations with Authors
    SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    In the newest podcast, SLAS Technology guest editors Dean Ho, Ph.D. and Ali Zarrinpar, M.D., Ph.D. of the University of California, Los Angeles, talk about the state of personalized and precision medicine (PPM) and how the 11 reviews and reports in the June 2017 special issue explore innovation from a cross section of the disciplines driving major advances.

    "With the advent of new technologies that can personalize care to individual patients dynamically — since physiologies in the same patient can change constantly — that really opens up new avenues to optimizing outcomes for all patients," says Ho. Access the issue's table of contents.


    Why Should YOU Present at SLAS2018?
    SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Your peers offer some reasons. "SLAS is one of the largest conferences that focuses on applied biological, bioengineering and chemical research, which is the driver of biological and pharmaceutical innovation," cite Benjamin Haley (Genentech) and Neville Sanjana (New York University), SLAS2018 Cellular Technologies Track chairs.

    "SLAS attracts a unique balance of industry and academic attendees, thus providing unusually broad opportunities for networking and collaboration. Presenting provides direct exposure for one's own or one's company's research to the most critical, but also helpful, audience — peers. The unique nature of SLAS — being focused on applied research — also invites the opportunity for questions or suggestions posed to the presenter that may inspire alternative uses or directions for the described material."

    SLAS Webinar On Demand: Modular, Fully Integrated or Collaborative Automation?
    SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
    The establishment of the AstraZeneca-Medical Research Council UK Centre for Lead Discovery led to revamping the company's screening infrastructure to embrace next generation high-throughput screening automation. How might your organization learn from AstraZeneca?

    Mark Wigglesworth recaps the experience from the AstraZeneca perspective, including what works, what scientists like, what best conforms to the demands of the assay and summarizes project learnings regarding collaborative robotics, remote operation and unforeseen benefits. This SLAS Webinar is free to dues-paying SLAS members.

    Sponsored Content


    CRISPR Can Cause Hundreds of Unintended Mutations
    Bioscience Technology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    As CRISPR-Cas9 starts to move into clinical trials, a new study published in Nature Methods has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome. "We feel it's critical that the scientific community consider the potential hazards of all off-target mutations caused by CRISPR, including single nucleotide mutations and mutations in non-coding regions of the genome," says co-author Stephen Tsang, MD, PhD. More

    Next Generation Precision-Polyesters Enabling Optimization of Ligand-Receptor Stoichiometry for Modular Drug Delivery
    Journal of the American Chemical Society    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    The success of receptor-mediated drug delivery primarily depends on the ability to optimize ligand–receptor stoichiometry. Conventional polyesters such as polylactide (PLA) or its copolymer, polylactide-co-glycolide (PLGA), do not allow such optimization due to their terminal functionality. We herein report the synthesis of 12 variations of the PLA–poly(ethylene glycol) (PEG) based precision-polyester (P2s) platform, permitting 5–12 periodically spaced carboxyl functional groups on the polymer backbone. More

    By Copying Bacterial Enzymes, Lab Quickly Learns to Synthesize New Class of Antibiotic Molecules Cleanly, Efficiently    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    The active component of the wonder drug penicillin and related antibiotics such as the cephalosporins is an "enchanted ring," called the β-lactam ring. Antibiotics that include these rings are arguably the most important drugs in human history, having singlehandedly increased global life expectancy by an estimated five years. "People often say we're running out of antibiotics, but there are more than 20,000 molecules with antibiotic activity in the Handbook of Antibiotics," said Timothy Wencewicz, a chemist at Washington University in St. Louis. More

    A Disease-Linked ULBP6 Polymorphism Inhibits NKG2D-Mediated Target Cell Killing By Enhancing the Stability of NKG2D Ligand Binding
    Science Magazine    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Natural killer (NK) cells target virally infected and transformed cells for cytolysis. When sufficient activating receptors on the NK cell surface, such as NKG2D, are engaged by ligands on the target cell, such as ULBP proteins, the NK cell kills the target. Polymorphisms within ULBP-encoding genes are associated with immune dysfunction. Zuo et al. found that the affinity of a commonly occurring ULBP6 variant for NKG2D was greater than that of the wild-type protein, which impaired NK cell activation. More

    Researchers Studying Century-Old Drug in Potential New Approach to Autism
    Lab Manager    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    In a small, randomized Phase I/II clinical trial (SAT1), researchers at University of California San Diego School of Medicine say a 100-year-old drug called suramin, originally developed to treat African sleeping sickness, was safely administered to children with autism spectrum disorder (ASD), who subsequently displayed measurable, but transient, improvement in core symptoms of autism. ASD encompasses a group of developmental disorders, often characterized by communication and language difficulties, repetitive behaviors and inability to socialize. More

    When Two Drugs Are Better Than One
    Chemical & Engineering News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    Drug combinations often have deleterious effects, but a new study reports a method to identify drugs that play nice with each other. Stefan Kubicek of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and coworkers compiled a compound library to search for drugs that work better together than alone, and they used it to identify a combo that fights drug-resistant cancer. The list of more than 30,000 Food & Drug Administration-approved drug products is too large to screen efficiently for favorable combinations. More

    DNA Sequencing Platform to Receive NIH Funding
    Genetic Engineering & Biotechnology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    SomaGenics announced it will receive a Phase I grant from NIH's National Human Genome Research Institute for a cell-free (cf) DNA liquid biopsy platform that will allow researchers to analyze and log single-stranded DNA fragments that are less than 100 nucleotides long. The platform, called RealSeq®-DC, is an extension of the company's existing platform, RealSeq®-AC, which permits the preparation of small RNA sequencing libraries. More

    New Chemical Reaction Could Eventually Yield New Fuels and Medications
    Science Daily    Share    Share on FacebookTwitterShare on LinkedinE-mail article
    A basic step toward creating new molecules is selectively breaking and re-forming the chemical bonds that connect the atoms that make them up. One of the chief challenges is that the bond between carbon and hydrogen atoms — the building blocks of many molecules — is exceptionally strong, so chemists often have to resort to using rare and expensive chemicals like iridium to convert it into other, more useful types of chemical bonds. Scientists refer to this process as "functionalizing" the bonds. More


    Sr. Laboratory Automation Engineer
    Oxford Immunotec
    US – MA – Norwood

    BioProduct Development Field Applications
    Molecular Devices LLC
    US – MA – Boston

    Search Jobs at SLAS Career Connections



    SLAS Point-to-Point
    Colby Horton, Vice President of Publishing, 469.420.2601
    Download media kit

    Dennis Hall, Executive Editor, 469.420.2656   
    Contribute news

    This edition of SLAS Point-to-Point was sent to ##Email##. To unsubscribe from receiving SLAS Point-to-Point, click here. To unsubscribe from all SLAS e-mail communications, please click here. Did someone forward this edition to you? Subscribe here — it's free!

    SLAS Terms of Use Policy

    MultiView Privacy Policy 

    Recent issues

    May 24, 2017
    May 17, 2017
    May 10, 2017
    May 3, 2017

    7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063